Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of CC-99677 in Healthy Males
NCT05284890Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamcemetinib in ankylosing spondylitis (AS), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum plasma concentration of CC-99677 up to 15 days, Time of maximum observed plasma concentration up to 15 days and 9 more. Started May 2022; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05284890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284890.